Ocuphire Pharma Announces Acquisition of Opus Genetics
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: GlobeNewswire
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy Projected cash runway extended into 2026 Conference call to discuss the acquisition to take place at 4:30 p.m. ET today FARMINGTON HILLS, Mich., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocup
Show less
Read more
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsPR Newswire
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public ShareholdersBusiness Wire
OCUP
Earnings
- 8/13/24 - Miss
OCUP
Analyst Actions
- 10/23/24 - Canaccord Genuity
OCUP
Sec Filings
- 12/30/24 - Form 4
- 10/24/24 - Form 4
- 10/24/24 - Form 4
- OCUP's page on the SEC website